A reference post rather than a discussion. Corrections are the point; I would rather this be right than mine. It is about glycaemic control, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.
The condition it depends on
The caveat that HbA1c is unreliable in anaemia, haemoglobinopathies and recent blood loss, all of which are commoner than people assume. If it disagrees with fasting glucose or a CGM, that is worth chasing.
The practical version
Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.
What I am not sure about
What I actually want to know is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner. Tell me what I have not thought of.
PeptideSynthNJ said:HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 19%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.
PeptideSynthNJ said:HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…
My labs after 3 months on glycaemic control: A1C 5.1%, fasting glucose 91 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 7.7% and fasting glucose was 126 mg/dL. The improvement has been dramatic and consistent.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.CardioMD said:My labs after 3 months on glycaemic control: A1C 5.1%, fasting glucose 91 mg/dL, fasting insulin 8 uIU/mL.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 122 | 100 | 94 | 84 |
| Insulin (fasting) | 18 | 14 | 10 | 7 |
| HOMA-IR | 4.5 | 3.3 | 2.2 | 1.1 |
| Uric Acid | 8.0 | 6.2 | 6.1 | 4.8 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.
BethLabQueen said:Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 19%.
Second this. I had assumed I was the exception until I read this.